A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926
Information source: Hoffmann-La Roche
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Rheumatoid Arthritis
Intervention: tocilizumab [RoActemra/Actemra] (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Hoffmann-La Roche Official(s) and/or principal investigator(s): Clinical Trials, Study Director, Affiliation: Hoffmann-La Roche
Summary
This multicenter, open-label, single arm, long-term extension study will evaluate the safety
and efficacy of RoActemra/Actemra (tocilizumab) in patients with early moderate to severe
rheumatoid arthritis who completed the WA19926 core study. Patients will receive
RoActemra/Actemra 8 mg/kg intravenously every 4 weeks for up to 104 weeks.
Clinical Details
Official title: A MULTICENTER, OPEN-LABEL, SINGLE ARM, LONG TERM EXTENSION STUDY OF WA19926 TO DESCRIBE SAFETY DURING TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH EARLY, MODERATE TO SEVERE RHEUMATOID ARTHRITIS
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Long-term safety: Incidence of adverse events
Secondary outcome: Change in disease activity: Disease Activity Score 28 - erythrocyte sedimentation rate (DAS28-ESR) and/or Simplified Disease Activity Index (SDAI)Change in total tender joint count (TJC) / swollen joint count (SJC) Proportion of patients achieving sustained drug-free remission, defined as clinical remission based on DAS28-ESR <2.6 and/or SDAI =3 for two consecutive visits (every 12 weeks) followed by RoActemra/Actemra discontinuation after the 2nd visit Time to rheumatoid arthritis flare in patients who have entered drug-free remission
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Patients who complete their last WA19926 core study visit (Week 104) and who may
benefit from study drug treatment according to the Investigator's assessment
- No current or recent adverse event or laboratory finding preventing the use of the
study drug dose of RoActemra/Actemra 8 mg/kg at baseline visit
- Receiving treatment on an outpatient basis
- Females of childbearing potential must agree to use at least one adequate method of
contraception, including a method with a failure rate of <1% per year, during the
treatment period
Exclusion Criteria:
- Pregnant or lactating women
- Patients who have prematurely withdrawn from the WA19926 core study for any reason
- Treatment with an investigational agent or cell-depleting therapies since the last
administration of study drug in the WA19926 core study
- Immunization with a live/attenuated vaccine since the last administration of study
drug in the WA19926 core study
- Diagnosis since last WA19926 visit (Week 104) of rheumatic autoimmune disease other
than rheumatoid arthritis
- Diagnosis since last WA19926 visit (Week 104) of inflammatory joint disease other
than rheumatoid arthritis
- Inadequate liver, hematologic or renal function
- History of severe allergic or anaphylactic reactions to humanized or murine
monoclonal antibodies
- Known active or history of recurrent infections
- Evidence of active malignant disease, malignancies within the previous 10 years
(except for basal cell carcinoma of the skin that has been excised and cured), or
breast cancer diagnosed within the previous 20 years
- Uncontrolled disease states, such as asthma or inflammatory bowel disease, where
flares are commonly treated with oral or parenteral corticosteroids
Locations and Contacts
Skopje 1000, Macedonia, The Former Yugoslav Republic of
Additional Information
Starting date: October 2012
Last updated: August 17, 2015
|